Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baker Hughes Co (BKR) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Baker Hughes CoTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Baker Hughes Co vs Citius Pharmaceuticals Inc — how do they compare? Baker Hughes Co trades at $64.87 (market cap $64.34B), while Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M). The key difference: Baker Hughes Co is far larger — about 3215.4× Citius Pharmaceuticals Inc's market cap, and Baker Hughes Co pays a 1.42% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BKRCTXR
Market Cap
$64.34B$20.01M
Sector
EnergyHealth
52-Week High
$69.67$1.82
52-Week Low
$42.51$0.48
Enterprise Value
$64.86B$16.23M
Dividend Yield
1.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baker Hughes Co

Baker Hughes (BKR) trades at $64.07, up 4.09% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.64 exceeding expectations. Recent contract wins in subsea systems and LNG technology, along with the Chart Industries acquisition, position the company for growth despite modest oil & gas spending headwinds. Operating cash flow reached $3.81 billion in 2025, supporting financial stability.

BKR presents a favorable risk-reward profile with 66.7% analyst buy ratings and a $73.25 consensus target offering 14% upside. Key risks include integration challenges from acquisitions and oil market volatility, but strong backlog and margin expansion support the bullish case. The stock remains attractive for investors seeking energy technology exposure with solid cash flow generation.

Citius Pharmaceuticals Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Baker Hughes Co

Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.

Read more on BKR

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR